Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Accuray Incorporated (ARAY-NASDAQ) |
|
|
“If you are a patient, you should remember that Accuray’s CyberKnife is an alternative to surgery. It’s a non-invasive, painless out-patient procedure. The Cyberknife can treat inoperable tumors, and even if operable, you don’t want to cut open the patient, crack open their rib cage, and deflate their lungs in order to treat a lung tumor or invasively treat a tumor that is wrapped around the spine. It may be inoperable in that case. Our technology offers the means to deliver high doses of radiation...” - Robert E. McNamara (ARAY) (Interview published May 30, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
|
Clinical Evidence Grows in Support of
CyberKnife Treatment for Intracranial and Extracranial Tumors
CyberKnife Users' Meeting Highlights Clinical Studies and Emerging Trends in Brain, Lung and Prostate Radiosurgery This year's CyberKnife Users' Meeting attracted more than 500
attendees, including surgeons, radiation oncologists, medical
physicists, hospital administrators and other related clinical
staff. More than 15 percent of those in attendance traveled from
outside of the At this year's meeting, nine presentations reported on large-scale studies, each with more than 100 patients with brain, lung or prostate tumors. The 2009 Users' Meeting included 11 presentations related to prostate cancer treatment, with follow-up data approaching three years for many patients. In addition to updated outcomes with longer follow-up, researchers are extending CyberKnife applications for prostate cancer beyond early-stage disease. For example, clinicians discussed their use of CyberKnife radiosurgery to "boost" the radiation dose after conventional radiation therapy for patients with advanced disease, as well as for the treatment of recurrent cancer in patients that failed conventional radiation therapy. The adoption of CyberKnife radiosurgery for the treatment of lung cancer continues to grow, a trend that was supported by 11 clinical lung cancer presentations. Presenters reported on primary and metastatic lung cancer, the treatment of recurrence after radiation therapy and chemotherapy, and quality of life after lung cancer treatment. In one study, patients showed 94 percent local control of lung tumors at a median follow-up of 33 months. CyberKnife advantages continue to be extended in brain cancer and other brain disorders. Multiple presentations highlighted the CyberKnife System's frameless capability to conveniently treat in multiple sessions -- a particularly beneficial capability when lesions are near sensitive critical structures such as those that control vision and hearing. In one study of 114 acoustic neuroma patients, the authors concluded that the CyberKnife System's abilities made radiosurgical treatment possible for more than 13 percent of patients who could not have been treated with single-session radiosurgery because of risk of hearing loss. "The presentations and posters at this year's Users' Meeting were
representative of the increased interest in CyberKnife radiosurgery,
particularly for the treatment of lung and prostate cancer, given
its unrivaled ability to accurately track and treat tumors that
move," said About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. About Safe Harbor Statement The foregoing may contain certain forward-looking statements that
involve risks and uncertainties, including uncertainties associated
with the medical device industry. Except for the historical
information contained herein, the matters set forth in this press
release, including statements relating to clinical studies,
regulatory review and approval, and commercialization of products
are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the
time those statements are made and/or management's good faith belief
as of that time with respect to future events. You should not put
undue reliance on any forward-looking statements. Important factors
that could cause actual performance and results to differ materially
from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our
products with complementary technology; and other risks detailed
from time to time under the heading "Risk Factors" in our report on
Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q
filed on SOURCE
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.